Rubius Therapeutics Inc. (RUBY)
0.06
0.00 (8.11%)
At close: Dec 29, 2023, 8:49 PM
8.11% (1D)
| Bid | n/a |
| Market Cap | 0 |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -233.75M |
| EPS (ttm) | -1.99 |
| PE Ratio (ttm) | -0.02864321608040201 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 755,858 |
| Avg. Volume (20D) | 99,535 |
| Open | 0.06 |
| Previous Close | 0.06 |
| Day's Range | 0.06 - 0.06 |
| 52-Week Range | 0.00 - 0.38 |
| Beta | 2.21 |
About RUBY
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 201...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 18, 2018
Employees 6
Stock Exchange NASDAQ
Ticker Symbol RUBY
Website https://www.rubiustx.com